Faricimab news

All news on Faricimab (also known as Vabysmo): plants, production capacities, investments and involved companies.

29 January 2026

Roche Reports 7% Sales Growth in 2025 Results

Pharmaceuticals and diagnostics drive profit and earnings growth. Key approvals and advancements in therapies. Dividend increase proposed. Board changes announced. Positive 2026 outlook.
17 October 2025

Roche Unveils Phase III Data for Vamikibart in Uveitic Macular Edema

Vamikibart shows promise in treating UME, with significant vision improvements in trials, offering a non-steroid alternative with fewer side effects.

Who will be producing Faricimab in the future?

Find out with chemXplore Analytics